Scribe Therapeutics develops a platform for CRISPR-based genetic medicine. The company focuses on molecular engineering and integrated technologies for therapeutic use in genetic medicine.

Scribe Therapeutics

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Scribe is enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification.

Prevail Therapeutics

Andreessen Horowitz

Avoro Capital Advisors

Avoro Ventures

Wellington Management

T. Rowe Price

Menlo Ventures

RA Capital Management

OrbiMed

Perceptive Advisors

Another summer, another annual beach day enjoyed with our Scribe family and friends! 

#NationalBeachDay #BayAreaBiotech

We will be at this week's Cold Spring Harbor Laboratory Genome Engineering: #CRISPR Frontiers meeting to share:

🧬 Our #CRISPRbyDesign approach
🧬 Advances in our epigenome editing platform and more

Looking forward to seeing you there to discuss how Scribe is engineering the future of epigenome editing!

#cshlcrispr24 #GeneEditing #EpigeneticEditing #GeneticMedicine #MolecularEngineering

Congratulations to our partners at Eli Lilly and Company on this new hub dedicated to accelerating genetic medicines!

What does the future of #healthcare look like? 

Our CEO Benjamin Oakes envisions one-and-done therapies that could treat conditions like cardiometabolic disease. In his TEDx Berkeley talk, he explains that engineering #CRISPR technology is key to developing effective genetic medicines for a broad range of diseases and helping underserved patients rewrite their genetic destinies.

Watch his full talk on the TEDx YouTube channel: https://lnkd.in/ghPuX9sq

TED Conferences University of California, Berkeley #GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

In BioSpace, Greg Slabodkin highlights our "data-driven engineering approach—CRISPR by Design—that enables Scribe to build systems that allow for different genome editing outcomes than what’s possible with Cas9." 

Read more about our genome and epigenome editing tools for developing in vivo #CRISPR-based genetic medicines for broad patient populations ➡️ https://ow.ly/HROE50T1n6R 

#GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

Next-generation #CRISPR technologies. In vivo therapies for sickle cell and cardiovascular disease. The future of genetic medicine, from gene editing to epigenetic editing.

At #AspenIdeasHealth, our CEO Benjamin Oakes, Nobel Laureate and Innovative Genomics Institute founder Jennifer Doudna, and CRISPR Therapeutics CEO Samarth Kulkarni discussed these topics and more.

Missed their Aspen Ideas discussion? Check out the video recording, now available on demand: https://lnkd.in/grDZ7wU7 

The Aspen Institute #CRISPRbyDesign #GeneEditing #MolecularEngineering #EpigeneticEditing #GeneticMedicine

Metric
Company Name	Scribe Therapeutics	CRISPR Biotech Engineering
Symbol
MSH ID	COM:SCRIBETX	COM:CRISPR-BTE
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	GB
Stage
Employee Count	125
Website	scribetx.com	crispr-bte.com
LinkedIn	scribe-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

SCRI

COM:SCRIBETX

Scribe Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue